NCT01603329

Brief Summary

The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication. The investigators will use behavioral economics to explore the best way to communicate the incentives to the physicians.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
734

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 16, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 22, 2012

Completed
10 days until next milestone

Study Start

First participant enrolled

June 1, 2012

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2014

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2014

Completed
Last Updated

October 23, 2015

Status Verified

October 1, 2015

Enrollment Period

1.7 years

First QC Date

May 16, 2012

Last Update Submit

October 22, 2015

Conditions

Medication Adherence

Keywords

medication adherencediabeteshypertensioncholesterolstatins

Outcome Measures

Primary Outcomes (1)

  • Medication Adherence

    The investigators will see how the treatment arms affect the targeted physicians' patients medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.

    Up to two years

Secondary Outcomes (2)

  • Demographic Controls for Physicians

    Up to two years

  • Demographic Controls for Patients

    Up to 2 years

Study Arms (11)

Comprehensive incentives + comprehensive communication

EXPERIMENTAL

Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Comp incentives + comp communication + non-white paper

EXPERIMENTAL

Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Focused incentives + focused com for oral diabetes medication

EXPERIMENTAL

Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Foc incentives + foc comm for Diabetes + non-white paper

EXPERIMENTAL

Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Focused incentives + focused comm for hypertension meds

EXPERIMENTAL

Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Foc incentives + comm for hypertension meds + non-white paper

EXPERIMENTAL

Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Focused incentives + focused comm for cholesterol meds

EXPERIMENTAL

Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Foc incentives +comm for cholesterol meds + non-white paper

EXPERIMENTAL

Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Comprehensive communiation

EXPERIMENTAL

Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Comprehensive communication + non-white paper

EXPERIMENTAL

Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Control Arm

EXPERIMENTAL

Physicians and their patient adherence is tracked, but they receive no intervention.

Other: Increasing Medication Adherence through Physician Incentives and Messaging

Interventions

Increasing Medication Adherence through Physician Incentives and MessagingOTHER

There are two treatments: 1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication. 2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes. When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart.

Also known as: Adherence
Comp incentives + comp communication + non-white paperComprehensive communiationComprehensive communication + non-white paperComprehensive incentives + comprehensive communicationControl ArmFoc incentives + comm for hypertension meds + non-white paperFoc incentives + foc comm for Diabetes + non-white paperFoc incentives +comm for cholesterol meds + non-white paperFocused incentives + focused com for oral diabetes medicationFocused incentives + focused comm for cholesterol medsFocused incentives + focused comm for hypertension meds

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Physician in the Humana network
  • Treats Humana Medicare Advantage Members
  • Has Humana Medicare Advantage members who are taking at least one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication, and who are less than 80% adherent.

You may not qualify if:

  • Practices with more than 10 physicians

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Humana, Inc

Louisville, Kentucky, 40202, United States

Location

MeSH Terms

Conditions

Medication AdherenceDiabetes MellitusHypertension

Condition Hierarchy (Ancestors)

Patient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehaviorGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • David I Laibson, Ph.D.

    National Bureau of Economic Research, Harvard University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 16, 2012

First Posted

May 22, 2012

Study Start

June 1, 2012

Primary Completion

February 1, 2014

Study Completion

March 1, 2014

Last Updated

October 23, 2015

Record last verified: 2015-10

Locations

US(1)